Benjamin Ostendorf
@ostendorflab.org
Physician scientist @ChariteBerlin.
Interested in tumor immunology, systems biology, and cancer biology.
Lab website: www.ostendorflab.org
Interested in tumor immunology, systems biology, and cancer biology.
Lab website: www.ostendorflab.org
Very interesting! The link leads to the ESPAC5 trial though, correct link here www.thelancet.com/journals/lan...
Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised tria...
This randomised trial did not show a difference in overall survival between neoadjuvant
FOLFIRINOX and neoadjuvant gemcitabine-based chemoradiotherapy in patients with resectable
or borderline resecta...
www.thelancet.com
September 11, 2025 at 10:52 AM
Very interesting! The link leads to the ESPAC5 trial though, correct link here www.thelancet.com/journals/lan...
Thanks so much, Veena 🙏🙂!
May 29, 2025 at 8:13 AM
Thanks so much, Veena 🙏🙂!
Thank you also to all funders, including bluesky-less Krebshilfe & Charité, and @bihatcharite.bsky.social
May 19, 2025 at 7:21 PM
Thank you also to all funders, including bluesky-less Krebshilfe & Charité, and @bihatcharite.bsky.social
Huge congratulations to Philipp for spearheading this and for all others involved. I hope you give it a spin and use it! Maybe some of the good folks at @varianteffect.bsky.social?
BEscreen
bescreen.ostendorflab.org
May 19, 2025 at 7:21 PM
Huge congratulations to Philipp for spearheading this and for all others involved. I hope you give it a spin and use it! Maybe some of the good folks at @varianteffect.bsky.social?